Welcome to our dedicated page for CANTA news (Ticker: CANTA), a resource for investors and traders seeking the latest updates and insights on CANTA stock.
Cantargia (CANTA) is a clinical-stage biotechnology company pioneering antibody therapies targeting IL1RAP for cancer and inflammatory diseases. This page provides investors and researchers with a centralized hub for tracking the company's latest scientific advancements, financial disclosures, and strategic developments.
Access real-time updates on clinical trial progress (including nadunolimab combinations), regulatory milestones, and peer-reviewed research directly from Cantargia. Our curated news feed ensures you stay informed about key initiatives in oncology and autoimmune disease treatment without market speculation or promotional content.
Key updates include developments in:
- Phase II trials for pancreatic cancer and NSCLC
- CAN10 antibody program for inflammatory conditions
- Collaborative research partnerships
- Financial performance and strategic direction
Bookmark this page for streamlined access to Cantargia's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review official SEC filings.
Cantargia (STO:CANTA) presented positive results from two clinical trials of nadunolimab combination therapy at the ESMO Congress 2024. The trials, involving 55 patients primarily with lung cancer and head and neck cancer, showed encouraging median survival times in patients previously treated with immunotherapy. Key findings include:
1. CANFOUR trial (40 NSCLC patients): Stronger efficacy in 2nd line patients, especially non-squamous (ORR 91%, OS 26.7 months).
2. CIRIFOUR trial (15 heavily pretreated patients): Median survival of 19.7 months and disease control rate of 60%.
The data suggest nadunolimab's potential in addressing unmet medical needs, particularly in patients who have progressed on checkpoint inhibitors like pembrolizumab.
